Related references
Note: Only part of the references are listed.Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs
Paul M. Kaye et al.
SEMINARS IN IMMUNOPATHOLOGY (2020)
A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity
Laura M. Alcantara et al.
MOLECULES (2020)
Cutaneous Leishmaniasis Updates in Diagnosis and Management
Naomi E. Aronson et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates
Freddie Bailey et al.
PLOS NEGLECTED TROPICAL DISEASES (2019)
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
Katrien Van Bocxlaer et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
Diana Caridha et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Protozoan persister-like cells and drug treatment failure
Michael P. Barrett et al.
NATURE REVIEWS MICROBIOLOGY (2019)
The impact of leishmaniasis on mental health and psychosocial well-being: A systematic review
Malini Pires et al.
PLOS ONE (2019)
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing
Susana Santos Braga
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art
Rebecca L. Charlton et al.
PARASITOLOGY (2018)
Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review
Issam Bennis et al.
BMC PUBLIC HEALTH (2018)
Leishmaniasis treatment: update of possibilities for drug repurposing
Valter Viana Andrade-Neto et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2018)
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
Victor Kande Betu Ku Mesu et al.
LANCET (2018)
Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
Gert-Jan Wijnant et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
Anke E. Kip et al.
CLINICAL PHARMACOKINETICS (2018)
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
Naomi Aronson et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2017)
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Saumya Srivastava et al.
PARASITES & VECTORS (2017)
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis
Diana Caridha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
Mozna Khraiwesh et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2016)
Social and Economic Burden of Human Leishmaniasis
Ifeoma Okwor et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2016)
Drug combination therapy increases successful drug repositioning
Wei Sun et al.
DRUG DISCOVERY TODAY (2016)
Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model
Katrien Van Bocxlaer et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes
Annelies Mondelaers et al.
PLOS ONE (2016)
The past, present, and future of Leishmania genomics and transcriptomics
Cinzia Cantacessi et al.
TRENDS IN PARASITOLOGY (2015)
A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis
Emily Rose Mears et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds
Joachim Mueller et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2015)
Investigational drugs for visceral leishmaniasis
Shyam Sundar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis
Anny Fortin et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
An Essential Type I Nitroreductase from Leishmania major Can Be Used to Activate Leishmanicidal Prodrugs
Andrew A. Voak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Leishmania Resistance to Miltefosine Associated with Genetic Marker
Sandrine Cojean et al.
EMERGING INFECTIOUS DISEASES (2012)
Quinone Oxidoreductase-2-Mediated Prodrug Cancer Therapy
Mark R. Middleton et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1954
Prashant Patel et al.
MOLECULAR THERAPY (2009)
Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen
Elizabeth R. Sharlow et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
Short report: Efficacy of miltefosine for Bolivian cutaneous leishmaniasis
Jaime Soto et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2008)
The prevention of the growth of Leishmania major progeny in BALB/c iron-loaded mice:: a process coupled to increased oxidative burst, the amplitude and duration of which depend on initial parasite developmental stage and dose
Sylvia Bisti et al.
MICROBES AND INFECTION (2006)
Clinical and experimental advances in treatment of visceral leishmaniasis
HW Murray
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
